1
|
Tomal F, Sausset A, Le Vern Y, Sedano L, Techer C, Lacroix-Lamandé S, Laurent F, Silvestre A, Bussière FI. Microbiota promotes recruitment and pro-inflammatory response of caecal macrophages during E. tenella infection. Gut Pathog 2023; 15:65. [PMID: 38098020 PMCID: PMC10720127 DOI: 10.1186/s13099-023-00591-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 12/03/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Eimeria genus belongs to the apicomplexan parasite phylum and is responsible for coccidiosis, an intestinal disease with a major economic impact on poultry production. Eimeria tenella is one of the most virulent species in chickens. In a previous study, we showed a negative impact of caecal microbiota on the physiopathology of this infection. However, the mechanism by which microbiota leads to the physiopathology remained undetermined. Macrophages play a key role in inflammatory processes and their interaction with the microbiota during E. tenella infection have never been investigated. We therefore examined the impact of microbiota on macrophages during E. tenella infection. Macrophages were monitored in caecal tissues by immunofluorescence staining with KUL01 antibody in non-infected and infected germ-free and conventional chickens. Caecal cells were isolated, stained, analyzed and sorted to examine their gene expression using high-throughput qPCR. RESULTS We demonstrated that microbiota was essential for caecal macrophage recruitment in E. tenella infection. Furthermore, microbiota promoted a pro-inflammatory transcriptomic profile of macrophages characterized by increased gene expression of NOS2, ACOD1, PTGS2, TNFα, IL1β, IL6, IL8L1, IL8L2 and CCL20 in infected chickens. Administration of caecal microbiota from conventional chickens to germ-free infected chickens partially restored macrophage recruitment and response. CONCLUSIONS Taken together, these results suggest that the microbiota enhances the physiopathology of this infection through macrophage recruitment and activation. Consequently, strategies involving modulation of the gut microbiota may lead to attenuation of the macrophage-mediated inflammatory response, thereby limiting the negative clinical outcome of the disease.
Collapse
Affiliation(s)
- F Tomal
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
- MixScience, 35170, Bruz, France
| | - A Sausset
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
| | - Y Le Vern
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
| | - L Sedano
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
| | | | | | - F Laurent
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
| | - A Silvestre
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France
| | - F I Bussière
- INRAE, Université de Tours, UMR ISP, 37380, Nouzilly, France.
| |
Collapse
|
2
|
Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, Gustave CA, Perpoint T, Barrey C, Pirnay JP, Resch G. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun 2022; 13:4239. [PMID: 35869081 PMCID: PMC9306240 DOI: 10.1038/s41467-022-31837-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 07/04/2022] [Indexed: 12/17/2022] Open
Abstract
Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance. Lytic bacteriophages (phages for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms. Here we report on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, we set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time. After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy. Here, the authors describe a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess successfully treated with a personalized combination of phage therapy and antibiotics.
Collapse
|
3
|
Labetoulle R, Rigaill J, Lleres-Vadeboin M, Grattard F, Pozzetto B, Cazorla C, Botelho-Nevers E, Boyer B, Dupieux-Chabert C, Laurent F, Verhoeven PO, Carricajo A. Evaluation of the MRSA/SA ELITe MGB Assay for the Detection of Staphylococcus aureus in Bone and Joint Infections. J Clin Microbiol 2022; 60:e0083521. [PMID: 34788112 PMCID: PMC8769721 DOI: 10.1128/jcm.00835-21] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 11/15/2021] [Indexed: 11/20/2022] Open
Abstract
Bone and joint infections represent a potentially devastating complication of prosthetic orthopedic joint replacement, thus requiring both rapid and appropriate antibiotic treatment. Staphylococcus aureus is one of the most common pathogens involved in this pathology. Being able to assert its presence is the first step of efficient patient management. This monocenter study evaluated the MRSA/SA ELITe MGB assay for the molecular detection of S. aureus and methicillin-resistant S. aureus (MRSA) in bone and joint biopsy specimens and synovial fluids. This test, together with conventional techniques, including standard cultures and the 16S rRNA amplification assay, was performed on 208 successive perioperative samples collected prospectively for 1 year obtained from 129 patients. Using conventional techniques, we detected a microbial pathogen in 76 samples from 58 patients, 40 of which were identified as S. aureus. The limit of detection (LOD) of the MRSA/SA ELITe MGB assay was experimentally determined for bone and joint biopsy specimens and synovial fluids using negative samples spiked with S. aureus ATCC 43300. The sensitivities of S. aureus detection with the MRSA/SA ELITe MGB assay were 82.5% (33/40 samples) and 97.5% (39/40 samples) using the manufacturer's LOD and an experimentally determined LOD, respectively. Interestingly, using the osteoarticular specific LOD, 15 additional samples were determined to be positive for S. aureus DNA with the MRSA/SA ELITe MGB assay; in all cases, these samples were obtained from patients considered to be infected with S. aureus according to their clinical and microbiological records. The results were available within 24 h, which could help to expedite therapeutic decisions.
Collapse
Affiliation(s)
- R. Labetoulle
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
| | - J. Rigaill
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - M. Lleres-Vadeboin
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| | - F. Grattard
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - B. Pozzetto
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
| | - C. Cazorla
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
- Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne, France
| | - E. Botelho-Nevers
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Department of Infectious Diseases, University Hospital of St-Etienne, St-Etienne, France
| | - B. Boyer
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
- Department of Orthopaedic Surgery, University Hospital of St-Etienne, St-Etienne, France
| | - C. Dupieux-Chabert
- CIRI, Centre International de Recherche en Infectiologie, Staphylococcal Pathogenesis Team, University of Lyon, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL, Lyon, France
- Department of Bacteriology, Institute for Infectious Agents, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
- French National Reference Center for Staphylococci, Lyon, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - F. Laurent
- CIRI, Centre International de Recherche en Infectiologie, Staphylococcal Pathogenesis Team, University of Lyon, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL, Lyon, France
- Department of Bacteriology, Institute for Infectious Agents, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
- French National Reference Center for Staphylococci, Lyon, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - P. O. Verhoeven
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| | - A. Carricajo
- Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France
- CIRI, Centre International de Recherche en Infectiologie, GIMAP team, University of Lyon, University of St-Etienne, INSERM, U1111, CNRS UMR5308, ENS de Lyon, UCBL, St-Etienne, France
- Interregional Reference Centre for Complex Bone and Joint Infection (CRIOAc Lyon, Associated Center), University Hospital of St-Etienne, St-Etienne, France
| |
Collapse
|
4
|
Ferry T, Kolenda C, Briot T, Lustig S, Batailler C, Leboucher G, Laurent F. Mise en place d’un centre de phagothérapie en France dédié aux infections ostéo-articulaires complexes : 4 ans d’expérience de multidisciplinarité et d’interactions multi-étapes. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Triffault-Fillit C, Mabrut E, Corbin K, Braun E, Becker A, Goutelle S, Chaudier P, Fessy MH, Dupieux C, Laurent F, Gunst S, Lustig S, Chidiac C, Ferry T, Valour F. Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study. J Antimicrob Chemother 2021; 75:2299-2306. [PMID: 32407512 DOI: 10.1093/jac/dkaa166] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 03/27/2020] [Accepted: 03/31/2020] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The use of piperacillin/tazobactam with vancomycin as empirical antimicrobial therapy (EAT) for prosthetic joint infection (PJI) has been associated with an increased risk of acute kidney injury (AKI), leading us to propose cefepime as an alternative since 2017 in our reference centre. OBJECTIVES To compare microbiological efficacy and tolerance of these two EAT strategies. METHODS All adult patients with PJI empirically treated with vancomycin+cefepime (n = 89) were enrolled in a prospective observational study and matched with vancomycin+piperacillin/tazobactam-treated historical controls (n = 89) according to a propensity score including age, baseline renal function and concomitant use of other nephrotoxic agents. The two groups were compared using Kaplan-Meier curve analysis, and non-parametric tests regarding the proportion of efficacious empirical regimen and the incidence of empirical therapy-related adverse events (AE). RESULTS Among 146 (82.0%) documented infections, the EAT was considered efficacious in 77 (98.7%) and 65 (98.5%) of the piperacillin/tazobactam- and cefepime-treated patients, respectively (P = 1.000). The rate of AE, particularly AKI, was significantly higher in the vancomycin+piperacillin/tazobactam group [n = 27 (30.3%) for all AE and 23 (25.8%) for AKI] compared with the vancomycin+cefepime [n = 13 (14.6%) and 6 (6.7%)] group (P = 0.019 and <0.001, respectively), leading to premature EAT discontinuation in 20 (22.5%) and 5 (5.6%) patients (P = 0.002). The two groups were not significantly different regarding their comorbidities, and AKI incidence was not related to vancomycin plasma overexposure. CONCLUSIONS Based on the susceptibility profile of bacterial isolates from included patients, microbiological efficacy of both strategies was expected to be similar, but vancomycin + cefepime was associated with a significantly lower incidence of AKI.
Collapse
Affiliation(s)
- C Triffault-Fillit
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - E Mabrut
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - K Corbin
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - E Braun
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - A Becker
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - S Goutelle
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,Service pharmaceutique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Université Claude Bernard Lyon 1, ISPB Faculté de Pharmacie de Lyon, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive, Lyon, France
| | - P Chaudier
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,Service de chirurgie orthopédique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - M H Fessy
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,Service de chirurgie orthopédique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.,Université Claude Bernard Lyon 1, Lyon, France
| | - C Dupieux
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, Université´ Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France.,Institut des agents infectieux, Laboratoire de bactériologie, Centre National de référence des staphylocoques, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - F Laurent
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, Université´ Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France.,Institut des agents infectieux, Laboratoire de bactériologie, Centre National de référence des staphylocoques, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - S Gunst
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,Service de chirurgie orthopédique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - S Lustig
- Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,Université Claude Bernard Lyon 1, Lyon, France.,Service de chirurgie orthopédique, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - C Chidiac
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France
| | - T Ferry
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, Université´ Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France
| | - F Valour
- Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Centre interrégional de référence pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.,CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, Université´ Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France
| |
Collapse
|
6
|
Pilmis B, de Ponfilly GP, Farfour E, Ranc AG, Fihman V, Bille E, Dortet L, Degand N, Morand P, Potron A, Mizrahi A, Laurent F, Le Brun C, Guillard T, Héry-Arnaud G, Piau C, Barraud O, Ruffier d'Epenoux L, Zahar JR, Le Monnier A. Epidemiology and clinical characteristics of Klebsiella spp. meningitis in France. Infect Dis Now 2021; 52:82-86. [PMID: 34091093 DOI: 10.1016/j.idnow.2021.05.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 04/30/2021] [Accepted: 05/25/2021] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To describe the epidemiology of Klebsiella spp. meningitis in France with respect to clinical and bacteriological data. METHODS We performed a four-year multicenter, retrospective, observational study. The primary objective was to provide a clinical description of patients with Klebsiella spp. meningitis. Secondary objectives were to compare community-acquired meningitis and healthcare-associated meningitis and to analyze factors associated with mortality. RESULTS We enrolled 131 patients with Klebsiella spp. meningitis. Eighty-two (62.6%) infections were reported following neurosurgery. Twenty-eight strains (21.4%) were resistant to third-generation cephalosporins (3GC). The median [IQR] cellularity was 980/mm3 [116-5,550], the median protein level was 5.67 [1.62-9] g/L and the median CSF glucose level was 2.5 [0-3.4] mmol/L. The in-hospital mortality rate was 23.6%. Community-acquired meningitis isolates were more frequently susceptible to 3GC than isolates from healthcare-associated meningitis (89.2% versus 72%; p=0.04). Comorbidities reported for patients with community-acquired meningitis were mainly diabetes mellitus and liver cirrhosis. In multivariate analysis, focal neurological disorder at the time of diagnosis was the only factor associated with in-hospital mortality (p=0.01). CONCLUSIONS Purulent meningitis caused by Klebsiella spp. needs to be considered in patients with community-acquired meningitis and pre-existing conditions, as well as in case of meningitis following neurosurgical procedures.
Collapse
Affiliation(s)
- B Pilmis
- Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France; Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France. Service de microbiologie clinique, GH Paris Saint-Joseph, 75014 Paris, France; Service de Maladies infectieuses et Tropicales, Hôpital Necker Enfants Malades, Paris, France.
| | - G Péan de Ponfilly
- Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France. Service de microbiologie clinique, GH Paris Saint-Joseph, 75014 Paris, France; Laboratoire de Bactériologie, Département des Agents infectieux, CHU Saint Louis-Lariboisière-Fernand Widal, APHP, 75010 Paris, France
| | - E Farfour
- Service de Biologie Clinique, Hôpital Foch, 92150 Suresnes, France
| | - A-G Ranc
- Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Lyon, France
| | - V Fihman
- Unité de Bactériologie, Groupe Hospitalier Henri Mondor, 94010 Créteil, France
| | - E Bille
- Laboratoire de Microbiologie, Hôpital Necker-Enfants Malades, 75015 Paris, France
| | - L Dortet
- Service de Bactériologie-Hygiène, CHU de Bicêtre, 94270 Le Kremlin-Bicêtre, France
| | - N Degand
- Laboratoire de Bactériologie, Hôpital Larchet, CHU Nice, 06202 Nice, France
| | - P Morand
- Université de Paris, Faculté de Médecine Paris Centre; Groupe hospitalier APHP-CUP, Service de Bactériologie, 75014 Paris, France
| | - A Potron
- Centre National de Référence de la résistance aux antibiotiques, Centre Hospitalier Universitaire de Besançon, UMR6249 CNRS Chrono-Environnement, Université de Franche-Comté, Besançon, France
| | - A Mizrahi
- Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France. Service de microbiologie clinique, GH Paris Saint-Joseph, 75014 Paris, France; Laboratoire de Microbiologie et Plateforme de dosage des anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - F Laurent
- Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Lyon, France
| | - C Le Brun
- Service de Bactériologie-Virologie-Hygiène, Hôpital Bretonneau, CHRU de Tours, 37000 Tours, France
| | - T Guillard
- Université de Reims-Champagne-Ardenne, Inserm UMR-S 1250 P3Cell, SFR CAP-Santé ; Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière-Parasitologie-Mycologie, Hôpital Robert Debré, CHU Reims, 51000 Reims, France
| | - G Héry-Arnaud
- Université de Brest, Inserm, UMR 1078, Unité de Bactériologie, CHRU de Brest, F-29200 Brest, France
| | - C Piau
- Service de Bactériologie-Hygiène hospitalière, CHU de Rennes, 35033 Rennes, France
| | - O Barraud
- Service de bactériologie, virologie, hygiène, CHU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges, France
| | - L Ruffier d'Epenoux
- Service de Bactériologie-Hygiène hospitalière, CHU de Nantes, Institut de Biologie, 9 quai Moncousu 44093, Cedex 1, Nantes, France
| | - J-R Zahar
- Hygiène Hospitalière Et Prévention du Risque Infectieux, CHU Avicenne, AP-HP, 125 rue de Stalingrad, 93000, Bobigny, France
| | - A Le Monnier
- Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France. Service de microbiologie clinique, GH Paris Saint-Joseph, 75014 Paris, France; Laboratoire de Bactériologie, Département des Agents infectieux, CHU Saint Louis-Lariboisière-Fernand Widal, APHP, 75010 Paris, France
| | | |
Collapse
|
7
|
Asselineau J, Duperron M, Zysman M, Laurent F, Ben-Lala I, Berger P, Thiébaut R, Frison E. Calcul de taille d’étude pour le développement d’un modèle de prédiction d’une aggravation d’une forme légère de COVID-19. Rev Epidemiol Sante Publique 2021. [PMCID: PMC8138905 DOI: 10.1016/j.respe.2021.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Introduction Le calcul de la taille d’étude pour le développement d’un modèle de prédiction clinique utilise encore souvent la règle empirique proposée par Peduzzi en 1996 qui recommande l’inclusion de 10 événements à prédire par paramètre envisagé dans le modèle de prédiction. Une nouvelle approche a été proposée par Riley et al. en 2020 pour répondre aux enjeux majeurs du développement d’un modèle de prédiction : précision des estimations et contrôle de l’optimisme sur les performances de prédiction. Nous rapportons ici l’application de cette approche pour le développement d’un modèle de prédiction combinant des facteurs cliniques, biologiques et d’imagerie pour prédire la survenue d’une aggravation d’une forme légère de COVID-19 chez des patients ayant des résultats d’imagerie thoracique compatibles ou typiques de la COVID-19. Méthodes La stratégie de modélisation envisagée était un modèle de régression logistique avec une sélection a priori de facteurs identifiés dans la littérature. Comme dans la règle empirique, la nouvelle approche nécessite de préciser l’incidence de l’événement à prédire et le nombre de paramètres envisagés dans le modèle de prédiction. La taille d’étude déterminée par cette approche doit satisfaire quatre critères : précision souhaitée pour l’incidence de l’événement ; précision souhaitée pour les prédictions individuelles (sous la forme d’un pourcentage d’erreur absolu moyen) ; niveau maximal souhaité de sur-ajustement aux données (facteur de réduction minimal) et d’optimisme (surestimation maximale du R2 de Nagelkerke). Pour les deux derniers critères, le calcul requiert de préciser le R2 de Cox–Snell qui, en l’absence d’éléments probants dans la littérature, peut être déterminé en faisant une hypothèse sur le niveau de performance attendu du modèle de prédiction en termes de pourcentage de la variation totale observée dans les données expliqué par le modèle. Résultats L’incidence de l’évènement à prédire a été fixée à 20 % selon les données de la littérature. Une revue de la littérature sur les modèles de prédiction développés dans le contexte d’infection à COVID-19 nous a conduits à envisager 16 paramètres dans le modèle. Nous avons suivi les recommandations des auteurs pour définir la précision souhaitée pour l’incidence d’événement (±0,05), le pourcentage d’erreur absolu moyen (5 %), le facteur de réduction minimal (3 0,9) et la surestimation maximale du critère de performance (£ 0,05). Nous avons fait varier le pourcentage de la variation totale observée dans les données expliqué par le modèle entre 10 et 50 %. Pour satisfaire l’ensemble des critères, la taille d’étude requise variait entre 587 et 2205 patients. Nous avons retenu l’hypothèse d’un pourcentage de variance expliqué de 25 % conduisant à l’inclusion de 829 patients pour le développement du modèle. Conclusion La nouvelle approche de calcul de taille d’étude permet de considérer dès la conception, des éléments majeurs qui favorisent le développement d’un modèle de prédiction clinique de qualité, en particulier la précision des probabilités individuelles de survenue de l’événement et le contrôle de l’optimisme. En contrepartie, elle nécessite une expertise statistique plus poussée que pour la règle empirique. Néanmoins, son application est possible même dans un délai court et devrait donc être systématiquement envisagée dans les études de développement d’un modèle de prédiction clinique.
Collapse
|
8
|
Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel MP, Wislez M, Westeel V, Zalcman G, Scherpereel A, Khalil A. [Recommendations of French specialists on screening for lung cancer]. Rev Mal Respir 2021; 38:310-325. [PMID: 33637394 DOI: 10.1016/j.rmr.2021.02.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 01/25/2021] [Indexed: 12/17/2022]
Affiliation(s)
- S Couraud
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, hôpital Lyon Sud, Pierre-Bénite, France; Intergroupe francophone de cancérologie thoracique, Paris, France.
| | - G Ferretti
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de radiologie diagnostique et interventionnel, CHU de Grenoble-Alpes, Grenoble, France
| | - B Milleron
- Intergroupe francophone de cancérologie thoracique, Paris, France
| | - A Cortot
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et oncologie thoracique, CHU de Lille, Lille, France
| | - N Girard
- Intergroupe francophone de cancérologie thoracique, Paris, France; Unité d'oncologie thoracique, institut Curie, Paris, France
| | - V Gounant
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| | - F Laurent
- Service de radiologie, CHU de Bordeaux, Pessac, France
| | - O Leleu
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie, centre hospitalier Abbeville, Abbeville, France
| | - E Quoix
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie, CHRU Strasbourg, Strasbourg, France
| | - M-P Revel
- Service de radiologie, hôpital Cochin, Paris, France
| | - M Wislez
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, hôpital Cochin, Paris, France
| | - V Westeel
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et cancérologie thoracique, CHU de Besançon, Besançon, France
| | - G Zalcman
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| | - A Scherpereel
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et oncologie thoracique, CHU de Lille, Lille, France
| | - A Khalil
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de radiologie, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| |
Collapse
|
9
|
Lassau N, Bousaid I, Chouzenoux E, Lamarque J, Charmettant B, Azoulay M, Cotton F, Khalil A, Lucidarme O, Pigneur F, Benaceur Y, Sadate A, Lederlin M, Laurent F, Chassagnon G, Ernst O, Ferreti G, Diascorn Y, Brillet P, Creze M, Cassagnes L, Caramella C, Loubet A, Dallongeville A, Abassebay N, Ohana M, Banaste N, Cadi M, Behr J, Boussel L, Fournier L, Zins M, Beregi J, Luciani A, Cotten A, Meder J. Three artificial intelligence data challenges based on CT and MRI. Diagn Interv Imaging 2020; 101:783-788. [DOI: 10.1016/j.diii.2020.03.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 03/12/2020] [Indexed: 02/07/2023]
|
10
|
Blanc D, Racine V, Khalil A, Deloche M, Broyelle JA, Hammouamri I, Sinitambirivoutin E, Fiammante M, Verdier E, Besson T, Sadate A, Lederlin M, Laurent F, Chassagnon G, Ferretti G, Diascorn Y, Brillet PY, Cassagnes L, Caramella C, Loubet A, Abassebay N, Cuingnet P, Ohana M, Behr J, Ginzac A, Veyssiere H, Durando X, Bousaïd I, Lassau N, Brehant J. Artificial intelligence solution to classify pulmonary nodules on CT. Diagn Interv Imaging 2020; 101:803-810. [PMID: 33168496 DOI: 10.1016/j.diii.2020.10.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 10/12/2020] [Accepted: 10/13/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE The purpose of this study was to create an algorithm to detect and classify pulmonary nodules in two categories based on their volume greater than 100 mm3 or not, using machine learning and deep learning techniques. MATERIALS AND METHOD The dataset used to train the model was provided by the organization team of the SFR (French Radiological Society) Data Challenge 2019. An asynchronous and parallel 3-stages pipeline was developed to process all the data (a data "pre-processing" stage; a "nodule detection" stage; a "classifier" stage). Lung segmentation was achieved using 3D U-NET algorithm; nodule detection was done using 3D Retina-UNET and classifier stage with a support vector machine algorithm on selected features. Performances were assessed using area under receiver operating characteristics curve (AUROC). RESULTS The pipeline showed good performance for pathological nodule detection and patient diagnosis. With the preparation dataset, an AUROC of 0.9058 (95% confidence interval [CI]: 0.8746-0.9362) was obtained, 87% yielding accuracy (95% CI: 84.83%-91.03%) for the "nodule detection" stage, corresponding to 86% specificity (95% CI: 82%-92%) and 89% sensitivity (95% CI: 84.83%-91.03%). CONCLUSION A fully functional pipeline using 3D U-NET, 3D Retina-UNET and classifier stage with a support vector machine algorithm was developed, resulting in high capabilities for pulmonary nodule classification.
Collapse
Affiliation(s)
- D Blanc
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - V Racine
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - A Khalil
- Department of Radiology, Neuroradiology unit, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard, 75018 Paris, France; Université de Paris, 75010, Paris, France
| | - M Deloche
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - J-A Broyelle
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - I Hammouamri
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | | | - M Fiammante
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - E Verdier
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - T Besson
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - A Sadate
- Department of Radiology and Medical Imaging, CHU Nîmes, University Montpellier, EA2415, 30029 Nîmes, France
| | - M Lederlin
- Department of Radiology, Hôpital Universitaire Pontchaillou, 35000 Rennes, France
| | - F Laurent
- Department of thoracic and cardiovascular Imaging, Respiratory Diseases Service, Respiratory Functional Exploration Service, Hôpital universitaire de Bordeaux, CIC 1401, 33600 Pessac, France
| | - G Chassagnon
- Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France & Université de Paris, 75006 Paris, France
| | - G Ferretti
- Department of Radiology and Medical Imaging, CHU Grenoble Alpes, 38700 Grenoble, France
| | - Y Diascorn
- Department of Radiology, Hôpital Universitaire Pasteur, Nice, France
| | - P-Y Brillet
- Inserm UMR 1272, Université Sorbonne Paris Nord, Assistance Publique-Hôpitaux de Paris, Department of Radiology, Hôpital Avicenne, 93430 Bobigny, France
| | - Lucie Cassagnes
- Department of radiology B, CHU Gabriel Montpied, 63003 Clermont-Ferrand, France
| | - C Caramella
- Department of Radiology, Institut Gustave Roussy, 94800 Villejuif, France
| | - A Loubet
- Department of Neuroradiology, Hôpital Gui-de-Chauliac, CHRU de Montpellier, 34000 Montpellier, France
| | - N Abassebay
- Department of Radiology, CH Douai, 59507 Douai, France
| | - P Cuingnet
- Department of Radiology, CH Douai, 59507 Douai, France
| | - M Ohana
- Department of Radiology, Nouvel Hôpital Civil, 67000 Strasbourg, France
| | - J Behr
- Department of Radiology, CHRU de Jean-Minjoz Besançon, 25030 Besançon, France
| | - A Ginzac
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - H Veyssiere
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - X Durando
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France; Department of Medical Oncology, Centre Jean Perrin, 63011 Clermont-Ferrand, France
| | - I Bousaïd
- Digital Transformation and Information Systems Division, Gustave Roussy, 94800 Villejuif, France
| | - N Lassau
- Multimodal Biomedical Imaging Laboratory Paris-Saclay, BIOMAPS, UMR 1281, Université Paris-Saclay, Inserm, CNRS, CEA, Department of Radiology, Institut Gustave Roussy, 94800, Villejuif, France
| | - J Brehant
- Department of Radiology, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
| |
Collapse
|
11
|
Laurent F. RETRAIT : COVID-19 et troubles du rythme. Ann Cardiol Angeiol (Paris) 2020:S0003-3928(20)30151-7. [PMID: 33958186 PMCID: PMC7531598 DOI: 10.1016/j.ancard.2020.09.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 09/25/2020] [Indexed: 11/03/2022]
Abstract
L’éditeur a le regret de vous informer que cet article a déjà été publié dans les Annales de cardiologie et d’angéiologie : https://doi.org/10.1016/j.ancard.2020.09.024 , cette seconde publication faite par erreur a été retirée. Vous pouvez consulter le site https://www.elsevier.com/about/our-business/policies/article-withdrawal pour de plus amples renseignements. L’éditeur vous prie d’accepter ses excuses pour ce désagrément.
Collapse
Affiliation(s)
- F Laurent
- Ramsay Santé, hôpital privé Jacques-Cartier, institut cardiovasculaire Paris Sud, avenue du Noyer-Lambert, 91300 Massy, France.
| |
Collapse
|
12
|
Tattevin P, Dinh A, Ghout I, Mouton W, Verdier MC, Laurent F, Lemaitre F, Gatin L, Saleh-Mghir A, Crémieux AC. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis. Int J Antimicrob Agents 2020; 56:106152. [PMID: 32898684 DOI: 10.1016/j.ijantimicag.2020.106152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 08/06/2020] [Accepted: 08/29/2020] [Indexed: 01/01/2023]
Abstract
Guidelines for the management of carbapenemase-producing Enterobacterales (CPE) infections recommend a combination of two active agents, including meropenem if the minimum inhibitory concentration (MIC) is ≤8 mg/L. The therapeutic equivalence of meropenem generics has been challenged. We compared the bactericidal activity of meropenem innovator (AstraZeneca) and four generic products (Actavis, Kabi, Mylan and Panpharma), both in vitro and in vivo, in association with colistin. In vitro time-kill studies were performed at 4 × MIC. An experimental model of KPC-producing Klebsiella pneumoniae osteomyelitis was induced in rabbits by tibial injection of a sclerosing agent followed by 2 × 108 CFU of K. pneumoniae KPC-99YC (meropenem MIC = 4 mg/L; colistin MIC = 1 mg/L). At 14 days after inoculation, treatment for 7 days started in seven groups of ≥10 rabbits, including a control group, a colistin group, and one group for each meropenem product (i.e. the innovator and four generics), in combination with colistin. In vitro, meropenem + colistin was bactericidal with no viable bacteria after 6 h, and this effect was similar with all meropenem products. In the osteomyelitis model, there was no significant difference between meropenem generics and the innovator when combined with colistin. Colistin-resistant strains were detected after treatment with colistin + meropenem innovator (n = 3) and generics (n = 3). The efficacy of four meropenem generics did not differ from the innovator in vitro and in an experimental rabbit model of KPC-producing K. pneumoniae osteomyelitis in terms of bactericidal activity and the emergence of resistance.
Collapse
Affiliation(s)
- P Tattevin
- Pontchaillou Univ. Hosp., Rennes, France; INSERM U1230, Université Rennes 1, IFR140, F-35033, Rennes, France.
| | - A Dinh
- UMR 1173, Versailles Saint-Quentin Université, Versailles, France; Raymond Poincaré Univ. Hosp., Garches, France
| | - I Ghout
- Ambroise Paré Univ. Hosp., Boulogne, France
| | | | - M-C Verdier
- Pontchaillou Univ. Hosp., Rennes, France; INSERM CIC 1414, Université Rennes 1, F-35033, Rennes, France
| | | | - F Lemaitre
- Pontchaillou Univ. Hosp., Rennes, France; INSERM CIC 1414, Université Rennes 1, F-35033, Rennes, France
| | - L Gatin
- UMR 1173, Versailles Saint-Quentin Université, Versailles, France; Raymond Poincaré Univ. Hosp., Garches, France
| | - A Saleh-Mghir
- UMR 1173, Versailles Saint-Quentin Université, Versailles, France
| | - A-C Crémieux
- UMR 1173, Versailles Saint-Quentin Université, Versailles, France; St Louis Hospital AP-HP, Université, Paris 7, France
| |
Collapse
|
13
|
Bartels MD, Worning P, Andersen LP, Bes M, Enger H, Ås CG, Hansen TA, Holzknecht BJ, Larssen KW, Laurent F, Mäkitalo B, Pichon B, Svartström O, Westh H. Repeated introduction and spread of the MRSA clone t304/ST6 in northern Europe. Clin Microbiol Infect 2020; 27:284.e1-284.e5. [PMID: 32439595 DOI: 10.1016/j.cmi.2020.05.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 03/13/2020] [Accepted: 05/03/2020] [Indexed: 12/21/2022]
Abstract
OBJECTIVES During the last decades several methicillin-resistant Staphylococcus aureus (MRSA) clones with the capability of global spread have emerged in the community. Here, we have investigated a large collection of clinical isolates belonging to MRSA clone t304/ST6, which has emerged in many European countries over the last years, in order to retrace its phylogeny and its spread. METHODS We characterized 466 ST6 isolates from Denmark (n = 354), France (n = 10), Norway (n = 24), Sweden (n = 27) and the UK (n = 51). All had spa-type t304 (n = 454) or t304-related spa-types (n = 12) and whole genome sequencing (WGS) was carried out on Illumina Miseq or Hiseq with 100-300 bp reads. cgMLST was performed using Ridom SeqSphere. RESULTS A minimum spanning tree (MST) of all 466 isolates showed one large cluster including 182 isolates collected only from Denmark and related to a long-term neonatal outbreak in Copenhagen. This cluster contrasted with numerous small clusters, including the remaining Danish isolates and isolates from the other countries that interspersed throughout the tree. Most isolates were Panton-Valentine leukocidin (PVL) negative (95%) and harboured SCCmec IVa. One genome was closed using Oxford Nanopore technology and Illumina MiSeq. It contained a plasmid of 19.769 bp including the blaZ gene. A similar plasmid was found in 78% of all isolates. DISCUSSION t304/ST6 is a successful emerging clone and the fact that isolates from five countries are interspersed throughout the MST indicates a common origin. This clone is commonly described in the Middle East and its emergence in Europe coincides with influx of refugees from the Syrian Civil War.
Collapse
Affiliation(s)
- M D Bartels
- Department of Clinical Microbiology, MRSA Knowledge Centre, Hvidovre Hospital, Denmark.
| | - P Worning
- Department of Clinical Microbiology, MRSA Knowledge Centre, Hvidovre Hospital, Denmark
| | - L P Andersen
- Department of Clinical Microbiology, Rigshospitalet, Denmark
| | - M Bes
- Institute for Infectious Agents - Department of Bacteriology, French National Reference Centre for Staphylococci, Lyon, France
| | - H Enger
- Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
| | - C G Ås
- Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
| | - T A Hansen
- Department of Clinical Microbiology, MRSA Knowledge Centre, Hvidovre Hospital, Denmark
| | - B J Holzknecht
- Department of Clinical Microbiology, Herlev Gentofte Hospital, Denmark
| | - K W Larssen
- Department of Medical Microbiology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
| | - F Laurent
- Institute for Infectious Agents - Department of Bacteriology, French National Reference Centre for Staphylococci, Lyon, France
| | - B Mäkitalo
- Public Health Agency of Sweden, Solna, Sweden
| | - B Pichon
- Public Health England, National Infection Service, London, UK
| | | | - H Westh
- Department of Clinical Microbiology, MRSA Knowledge Centre, Hvidovre Hospital, Denmark; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
14
|
Bonnet G, Pernot M, Welte N, Peltan J, Seguy B, Dijos M, Laurent F, Ouattara A, Lafitte S, Ritter P, Bordachar P, Labrousse L, Leroux L. Post-TAVR conduction disorders: Membranous septum role. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Durand T, Vautrin F, Bergeron E, Girard V, Polsinelli S, Monnin V, Durand G, Dauwalder O, Dumitrescu O, Laurent F, Rodríguez-Nava V. Assessment of VITEK® MS IVD database V3.0 for identification of Nocardia spp. using two culture media and comparing direct smear and protein extraction procedures. Eur J Clin Microbiol Infect Dis 2019; 39:559-567. [PMID: 31758438 DOI: 10.1007/s10096-019-03758-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 10/30/2019] [Indexed: 02/06/2023]
Abstract
We assessed the performance of the VITEK® MS IVD V3.0 matrix-assisted laser desorption ionization - time of flight mass spectrometry (MALDI-ToF MS) V3.0 database for the identification of Nocardia spp. as compared with targeted DNA sequencing. A collection of 222 DNA sequence-defined Nocardia spp. strains encompassing 18 different species present or not in the database was tested. Bromocresol purple agar (BCP) and Columbia agar +5% sheep's blood (COS) culture media were used together with two different preparation steps: direct smear and a "3 attempts" procedure that covered (1) spotting of an extract, (2) new spotting of the same extract, and (3) spotting of a new extract. The direct smear protocol yielded low correct identification rates (≤ 15% for both media) whereas protein extraction yielded correct identification results (> 67% regardless of the media used.). The use of 2 additional attempts using repeat or new extracts increased correct identification rates to 87% and 91% for BCP and COS, respectively. When using the 3 attempts procedure, the best identification results, independent of media types, were obtained for N. farcinica and N. cyriacigeorgica (100%). Identification attempts 2 and 3 allowed to increase the number of correct identifications (BCP, +20%; COS, +13%). The enhancement in performance during attempts 2 and 3 was remarkable for N. abscessus (81% for both media) and low prevalence species (BCP, 70%; COS, 85%). Up to 3.4% and 2.4% of the strains belonging to species present in the database were misidentified with BCP and COS media, respectively. In 1.9% of the cases for BCP and 1.4% for COS, these misidentifications concerned a species belonging to the same phylogenetic complex. Concerning strains that are not claimed in the V3.0 database, N. puris and N. goodfellowi generated "No identification" results and 100% of the strains belonging to N. arthritidis, N.cerradoensis, and N. altamirensis yielded a misidentification within the same phylogenetic complex. Vitek® MS IVD V3.0 is an accurate and useful tool for identification of Nocardia spp.
Collapse
Affiliation(s)
- T Durand
- Institut des Agents infectieux, Centre de Biologie et Pathologies Nord, Hôpital de la Croix Rousse, Lyon, France
| | - F Vautrin
- UMR CNRS 5557, Ecologie Microbienne - Groupe de Recherche "Pathogènes Opportunistes et Environnement" - ISPB-Faculté de Pharmacie, Université Lyon 1, Lyon, France
| | - E Bergeron
- UMR CNRS 5557, Ecologie Microbienne - Groupe de Recherche "Pathogènes Opportunistes et Environnement" - ISPB-Faculté de Pharmacie, Université Lyon 1, Lyon, France
| | - V Girard
- bioMérieux France, Microbiology R&D, La Balme-les-Grottes, France
| | - S Polsinelli
- bioMérieux France, Microbiology R&D, La Balme-les-Grottes, France
| | - V Monnin
- bioMérieux France, Microbiology R&D, La Balme-les-Grottes, France
| | - G Durand
- bioMérieux France, Microbiology R&D, La Balme-les-Grottes, France
| | - O Dauwalder
- Institut des Agents infectieux, Centre de Biologie et Pathologies Nord, Hôpital de la Croix Rousse, Lyon, France
| | - O Dumitrescu
- Institut des Agents infectieux, Centre de Biologie et Pathologies Nord, Hôpital de la Croix Rousse, Lyon, France
| | - F Laurent
- Institut des Agents infectieux, Centre de Biologie et Pathologies Nord, Hôpital de la Croix Rousse, Lyon, France
| | - V Rodríguez-Nava
- Institut des Agents infectieux, Centre de Biologie et Pathologies Nord, Hôpital de la Croix Rousse, Lyon, France. .,UMR CNRS 5557, Ecologie Microbienne - Groupe de Recherche "Pathogènes Opportunistes et Environnement" - ISPB-Faculté de Pharmacie, Université Lyon 1, Lyon, France.
| |
Collapse
|
16
|
Engelhardt J, Nunes M, Pouchieu C, San-Galli F, Gimbert E, Vignes J, Laurent F, Berge J, Baldi I, Tabarin A, Loiseau H. P09.08 Increased incidence of intracranial meningiomas in patients with acromegaly. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
An increased incidence of various neoplasms has been described in patients with acromegaly and there is evidence to suggest that growth factors are risk factors for the development of meningiomas. We aimed to study if patients with acromegaly are more at risk for developing intracranial meningiomas
MATERIAL AND METHODS
We conducted an observational study on 221 consecutive acromegalic patients recruited between January 1, 2000 and December 31, 2015, and 357 consecutive patients with a non-somatotropic pituitary adenoma recruited between March 1, 2015 and December 31, 2016 in our institution. Patients underwent a gadolinium-enhanced 3D T1 brain MRI to look for meningiomas. The proportion of meningiomas was compared between the two groups and the standardized incidence ratio (SIR) was computed from the incidence rates of meningiomas observed in the population of acromegalic patients and compared to that of the general population given by the local registry of central nervous system tumors.
RESULTS
Patients with acromegaly had a significant risk for developing intracranial meningiomas as compared to patients without acromegaly (7.7% vs. 2.2%, p = .005, OR = 3.45 [1.46; 8.15]). There was a significant increased incidence of intracranial meningiomas in patients with acromegaly (SIR = 126 [25; 367]) as compared to the general population.
CONCLUSION
Our study provides the first evidence that patients with acromegaly are more at risk for developing intracranial meningiomas.
Collapse
Affiliation(s)
| | - M Nunes
- CHU de Bordeaux, Bordeaux, France
| | - C Pouchieu
- Université de Bordeaux, Bordeaux, France
| | | | | | - J Vignes
- CHU de Bordeaux, Bordeaux, France
| | | | - J Berge
- CHU de Bordeaux, Bordeaux, France
| | - I Baldi
- Université de Bordeaux, Bordeaux, France
| | | | | |
Collapse
|
17
|
Gatin L, Mghir AS, Mouton W, Laurent F, Ghout I, Rioux-Leclercq N, Tattevin P, Verdier MC, Cremieux AC. Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection. Int J Antimicrob Agents 2019; 54:456-462. [PMID: 31319190 DOI: 10.1016/j.ijantimicag.2019.07.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 06/29/2019] [Accepted: 07/10/2019] [Indexed: 11/29/2022]
Abstract
Carbapenemase-producing Enterobacteriaceae (CPE) are emerging multidrug-resistant bacteria responsible for invasive infections, including prosthetic joint infections (PJIs). Local administration of colistin may provide bactericidal concentrations in situ. This study evaluated the efficacy of a colistin-impregnated cement spacer, alone and in combination with systemic antibiotics, in a rabbit model of CPE-PJI. Elution of 3 MIU of colistimethate sodium (CMS) in 40 g of poly(methyl methacrylate) cement was studied in vitro. In vivo, 5 × 108 CFU of KPC-producing Klebsiella pneumoniae (colistin and meropenem MICs of 1 mg/L and 4 mg/L, respectively) were injected close to a prosthetic knee. Surgical debridement and prosthesis removal were performed 7 days later, and rabbits were assigned to six treatment groups (11-13 rabbits each): drug-free spacer; colistin-loaded spacer; colistin intramuscular (i.m.); colistin i.m. + colistin spacer; colistin i.m. + meropenem subcutaneous (s.c.); and colistin i.m. + meropenem s.c. + colistin spacer. Systemic treatment was administered at doses targeting pharmacokinetics in humans, and rabbits were euthanised 7 days later to evaluate bacterial counts in infected bones. In vitro, CMS elution was low (<0.1% at 24 h) but reached a local concentration of ≥20 mg/L (>20 × MIC). In vivo, combinations of local and systemic colistin, with or without meropenem, were the only regimens superior to the control group (P ≤ 0.05) in terms of viable bacterial counts and the proportion of rabbits with sterile bone, with no emergence of colistin-resistant strains. Colistin-loaded cement spacer in combination with systemic antibiotics were the most effective regimens in this CPE-PJI model.
Collapse
Affiliation(s)
- L Gatin
- UMR U1173 Université Versailles St-Quentin, Versailles, France; Service d'Orthopédie et traumatologie, Hôpital Raymond Poincaré, Garches, France
| | - A Saleh Mghir
- UMR U1173 Université Versailles St-Quentin, Versailles, France
| | - W Mouton
- Laboratoire de Bactériologie, Hôpital de la Croix Rousse, Centre National de Référence des Staphylocoques Unité Inserm 851, Faculté de Médecine Lyon Est, Lyon, France
| | - F Laurent
- Laboratoire de Bactériologie, Hôpital de la Croix Rousse, Centre National de Référence des Staphylocoques Unité Inserm 851, Faculté de Médecine Lyon Est, Lyon, France
| | - I Ghout
- URC Paris-Ouest, Laboratoire de Biostatistiques, Hôpital Ambroise Paré, Boulogne-Billancourt, France
| | - N Rioux-Leclercq
- Service d'Anatomopathologie, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - P Tattevin
- Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, CHU de Rennes, 2 rue Henri Le Guilloux, 35033 Rennes Cedex, France.
| | - M C Verdier
- Laboratoire de Pharmacologie Biologique, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - A C Cremieux
- UMR U1173 Université Versailles St-Quentin, Versailles, France; Service des maladies infectieuses Hôpital Saint Louis AP-HP, Université Paris 7, Paris, France
| |
Collapse
|
18
|
Kolenda C, Josse J, Medina M, Fevre C, Lustig S, Ferry T, Laurent F. Évaluation de l’efficacité d’un assemblage de trois bactériophages anti Staphyloccocus aureus contre les bactéries au sein du biofilm ou internalisées dans les ostéoblastes. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
De Michèle S, Kabuth B, Plun O, Le Moal L, Laurent F, Vandelet E, Prudent C, De Tychey C. Index de contenu traumatique au Rorschach (TCI) et diagnostic de l’abus sexuel chez l’enfant. Annales Médico-psychologiques, revue psychiatrique 2019. [DOI: 10.1016/j.amp.2018.03.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Langlet B, Dournes G, Laurent F. CT features of pulmonary interstitial emphysema. Diagn Interv Imaging 2019; 100:825-826. [PMID: 31053558 DOI: 10.1016/j.diii.2019.04.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 04/10/2019] [Accepted: 04/11/2019] [Indexed: 11/28/2022]
Affiliation(s)
- B Langlet
- Department of Cardiovascular and Thoracic Imaging, CHU de Bordeaux, 33600 Pessac, France.
| | - G Dournes
- Department of Cardiovascular and Thoracic Imaging, CHU de Bordeaux, 33600 Pessac, France; Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, Bordeaux University, 33000 Bordeaux, France
| | - F Laurent
- Department of Cardiovascular and Thoracic Imaging, CHU de Bordeaux, 33600 Pessac, France; Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, Bordeaux University, 33000 Bordeaux, France
| |
Collapse
|
21
|
Butin M, Claris O, Laurent F. Clinical impact of vancomycin heteroresistance in staphylococcal strains involved in neonatal sepsis: Discussion of a case report. Arch Pediatr 2019; 26:236-237. [PMID: 30954366 DOI: 10.1016/j.arcped.2019.03.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Revised: 02/04/2019] [Accepted: 03/07/2019] [Indexed: 11/25/2022]
Abstract
Heteroresistance to vancomycin (HRV) represents a decreased susceptibility to vancomycin and is frequently observed in multidrug-resistant coagulase-negative staphylococci. The clinical significance of such heteroresistance is controversial, but several failures of vancomycin therapy have been related to HRV, especially in the neonatal population. Here we report the case of a preterm neonate, born at 26 weeks of gestation, who developed sepsis due to a multidrug-resistant HRV Staphylococcuscapitis isolate. Bacteremia persisted despite adequate vancomycin serum concentration and catheter removal. The patient finally recovered after replacing vancomycin by linezolid. Through this case report, we would like to alert clinicians of the potential clinical impact of HRV and to discuss the lack of therapeutic alternatives in neonates.
Collapse
Affiliation(s)
- M Butin
- Service de néonatologie et réanimation néonatale, hospices civils de Lyon, hôpital femme-mère-enfant, 59, boulevard Pinel, 69677 Bron cedex, France; Équipe « Pathogénèse des infections à Staphylocoques », Inserm U1111, centre international de recherche en infectiologie, 46, allée d'Italie, 69364 Lyon cedex 07, France.
| | - O Claris
- Service de néonatologie et réanimation néonatale, hospices civils de Lyon, hôpital femme-mère-enfant, 59, boulevard Pinel, 69677 Bron cedex, France; EA 4129, université Claude-Bernard, boulevard du 11-novembre-1918, 69100 Villeurbanne, France
| | - F Laurent
- Équipe « Pathogénèse des infections à Staphylocoques », Inserm U1111, centre international de recherche en infectiologie, 46, allée d'Italie, 69364 Lyon cedex 07, France; Centre national de référence des staphylocoques, groupement hospitalier est, hospices civils de Lyon, Institut des agents infectieux, 59, boulevard Pinel, 69677 Bron cedex, France
| |
Collapse
|
22
|
Laurent F, Butin M. Staphylococcus capitis and NRCS-A clone: the story of an unrecognized pathogen in neonatal intensive care units. Clin Microbiol Infect 2019; 25:1081-1085. [PMID: 30928561 DOI: 10.1016/j.cmi.2019.03.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 02/07/2019] [Accepted: 03/09/2019] [Indexed: 01/24/2023]
Abstract
BACKGROUND In neonatal intensive care units (NICUs), nosocomial late-onset sepsis (LOS), mostly due to coagulase negative staphylococci, constitute a major cause of death or impairment. Staphylococcus capitis, usually considered as a poorly virulent species, has been reported as a cause of LOS. OBJECTIVES To review data regarding S. capitis neonatal LOS and the features of isolates involved. SOURCES PubMed was searched up to August 2018 to retrieve studies on the topic; the keywords used were 'S. capitis', 'neonate', 'neonatal ICU', 'bloodstream infection' and 'late onset sepsis'. CONTENT Published data highlight the worldwide endemicity of a single S. capitis clone, named NRCS-A, specifically involved in LOS. NRCS-A harbours a multidrug resistance profile (including resistance to the usual first-line antibiotics used in NICUs). It is also able to adapt under vancomycin selective pressure that could confer an advantage for its implantation and dissemination in NICUs where this selective pressure is high. Moreover, a severe morbidity has been observed in NRCS-A-related LOS. The NICU environment, and especially incubators, constitute reservoirs of NRCS-A from which it could diffuse inside the setting. Finally, the virulome and resistome of S. capitis NRCS-A contain many genes potentially implicated in its specific epidemiology and pathophysiology, including the gene nsr that may be involved in its fitness and implantation in neonatal gut flora. IMPLICATIONS S. capitis must be considered as a true pathogen in neonates. The decreased susceptibility to vancomycin may be involved in failure of vancomycin therapy. Further studies are needed to better manage its diffusion inside each NICU but also worldwide.
Collapse
Affiliation(s)
- F Laurent
- Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 46 Allée d'Italie 69364 Lyon Cedex 07, France; Centre National de Référence des Staphylocoques, Hospices Civils de Lyon, 103 Grande Rue de La Croix Rousse, 69004 Lyon, France; Département de Microbiologie et Mycologie, Institut des Sciences Pharmaceutiques et Biologiques de Lyon, Université de Lyon, 6 Avenue Rockefeller, 69008 Lyon, France
| | - M Butin
- Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 46 Allée d'Italie 69364 Lyon Cedex 07, France; Réanimation Néonatale, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Bd Pinel 69500 Bron, France.
| |
Collapse
|
23
|
Cochet H, Iriart X, Allain-Nicolaï A, Jalal Z, Dinet M, Fournier E, Thambo J, Montaudon M, Laurent F. Focal scar and diffuse myocardial fibrosis in patients with history of repaired tetralogy of Fallot. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Palussière J, Chomy F, Savina M, Deschamps F, Gaubert JY, Renault A, Bonnefoy O, Laurent F, Meunier C, Bellera C, Mathoulin-Pelissier S, de Baere T. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg 2018; 13:91. [PMID: 30143031 PMCID: PMC6109264 DOI: 10.1186/s13019-018-0773-y] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 06/26/2018] [Indexed: 12/19/2022] Open
Abstract
Background A prospective multicenter phase II trial to evaluate the survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung cancer (NSCLC), ineligible for surgery. Methods Patients with a biopsy-proven stage IA NSCLC, staging established by a positron emission tomography-computed tomography (PET-CT), were eligible. The primary objective was to evaluate the local control of RFA at 1-year. Secondary objectives were 1- and 3-year overall survival (OS), 3-year local control, lung function (prior to and 3 months after RFA) and quality of life (prior to and 1 month after RFA). Results Of the 42 patients (mean age 71.7 y) that were enrolled at six French cancer centers, 32 were eligible and assessable. Twenty-seven patients did not recur at 1 year corresponding to a local control rate of 84.38% (95% CI, [67.21–95.72]). The local control rate at 3 years was 81.25% (95% CI, [54.35–95.95]). The OS rate was 91.67% (95% CI, [77.53–98.25]) at 1 year and 58.33% (95% CI, [40.76–74.49]) at 3 years. The forced expiratory volume was stable in most patients apart from two, in whom we observed a 10% decrease. There was no significant change in the global health status or in the quality of life following RFA. Conclusion RFA is an efficient treatment for medically inoperable stage IA NSCLC patients. RFA is well tolerated, does not adversely affect pulmonary function and the 3-year OS rate is comparable to that of stereotactic body radiotherapy, in similar patients. Trial registration ClinicalTrials.gov Identifier NCT01841060 registered in November 2008.
Collapse
Affiliation(s)
- J Palussière
- Department of Interventional Radiology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.
| | - F Chomy
- Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France
| | - M Savina
- Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France
| | - F Deschamps
- Department of Interventional Imaging, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, Paris, France
| | - J Y Gaubert
- Department of Imaging, CHU Timone, 264 Rue Saint-Pierre, 13385, Marseille, France
| | - A Renault
- Department of Imaging, CHU Pau, 4 Boulevard Hauterive, 64000, Pau, France
| | - O Bonnefoy
- Department of Imaging, CHU Pau, 4 Boulevard Hauterive, 64000, Pau, France
| | - F Laurent
- Department of Imaging, CHU Haut Lévêque, Avenue Magellan, 33600, Pessac, France
| | - C Meunier
- Department of Imaging, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes, France
| | - C Bellera
- Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France
| | - S Mathoulin-Pelissier
- Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France
| | - T de Baere
- Department of Interventional Imaging, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, Paris, France
| |
Collapse
|
25
|
Abad L, Diot A, Tasse J, Josse J, Lustig S, Ferry T, Laurent F, Valour F. Traitement des infections ostéoarticulaires à S . aureus : activité intraostéoblastiques des rifamycines et impact sur l’émergence intracellulaire de Small Colony Variants. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Cavalli Z, Becker A, Triffault-Filit C, Bosch A, Roux S, Valour F, Laurent F, Cohen S, Chidiac C, Ferry T. Évaluation de l’utilisation de la céfoxitine en association en administration parentérale continue dans le traitement des infections ostéoarticulaires. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Clerc A, Becker A, Conrad A, Batailler C, Valour F, Laurent F, Lustig S, Fessy M, Chidiac C, Ferry T. Infection de prothèse et changement en 1 temps : prétraitement par antibiothérapie ciblée chez des patients à risque. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Triffault-Fillit C, Ferry T, Laurent F, Pradat P, Dupieux C, Conrad A, Becker A, Lustig S, Fessy MH, Chidiac C, Valour F. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. Clin Microbiol Infect 2018; 25:353-358. [PMID: 29803842 DOI: 10.1016/j.cmi.2018.04.035] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Revised: 04/17/2018] [Accepted: 04/30/2018] [Indexed: 02/01/2023]
Abstract
OBJECTIVES The high microbiologic diversity encountered in prosthetic joint infection (PJI) makes the choice of empirical antimicrobial therapies challenging, especially in cases of implant retention or one-stage exchange. Despite the risk of dysbiosis and toxicity, the combination of vancomycin with a broad-spectrum β-lactam is currently recommended in all cases, even if Gram-negative bacilli (GNB) might be less represented in late PJI. In this context, this study aimed to describe the microbiologic epidemiology of PJI according to the chronology of infection. METHODS This prospective cohort study (2011-2016) evaluated the microbiologic aetiology of 567 PJI according to time of occurrence from prosthesis implantation-early (<3 months), delayed (3-12 months) and late (>12 months)-as well as mechanism of acquisition. RESULTS Initial microbiologic documentation (n = 511; 90.1%) disclosed 164 (28.9%) Staphylococcus aureus (including 26 (16.1%) methicillin-resistant S. aureus), 162 (28.6%) coagulase-negative staphylococci (including 81 (59.1%) methicillin-resistant coagulase-negative staphylococci), 80 (14.1%) Enterobacteriaceae, 74 (13.1%) streptococci and 60 (10.6%) Cutibacterium acnes. Considering nonhaematogenous late PJI (n = 182), Enterobacteriaceae (n = 7; 3.8%) were less represented than in the first year after implantation (n = 56; 17.2%; p <0.001), without difference regarding nonfermenting GNB (4.6% and 2.7%, respectively). The prevalence of anaerobes (n = 40; 21.9%; including 32 (80.0%) C. acnes) was higher in late PJI (p <0.001). Consequently, a broad-spectrum β-lactam might be useful in 12 patients (6.6%) with late PJI only compared to 66 patients (20.3%) with early/delayed PJI (p <0.001). CONCLUSIONS Considering the minority amount of GNB in late postoperative PJI, the empirical use of a broad-spectrum β-lactam should be reconsidered, especially when a two-stage exchange is planned.
Collapse
Affiliation(s)
- C Triffault-Fillit
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France.
| | - T Ferry
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - F Laurent
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service de microbiologie, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - P Pradat
- INSERM U1052, Center for Clinical Research, Croix-Rousse Hospital, Lyon, France
| | - C Dupieux
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service de microbiologie, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - A Conrad
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - A Becker
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France
| | - S Lustig
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service de chirurgie orthopédique, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - M H Fessy
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service de chirurgie orthopédique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - C Chidiac
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | - F Valour
- Centre de référence interrégional pour la prise en charge des infections ostéo-articulaires complexes (CRIOAc Lyon), Lyon, France; Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France
| | | |
Collapse
|
29
|
Cohen JG, Reymond E, Medici M, Lederlin M, Lantuejoul S, Laurent F, Toffart AC, Moreau-Gaudry A, Jankowski A, Ferretti GR. CT-texture analysis of subsolid nodules for differentiating invasive from in-situ and minimally invasive lung adenocarcinoma subtypes. Diagn Interv Imaging 2018; 99:291-299. [PMID: 29477490 DOI: 10.1016/j.diii.2017.12.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 12/11/2017] [Accepted: 12/21/2017] [Indexed: 12/17/2022]
Abstract
PURPOSE The purpose of this study was to evaluate the usefulness of computed tomography-texture analysis (CTTA) in differentiating between in-situ and minimally-invasive from invasive adenocarcinomas in subsolid lung nodules (SSLNs). MATERIAL AND METHODS Two radiologists retrospectively reviewed 49 SSLNs in 44 patients. There were 27 men and 17 women with a mean age of 63±7 (SD) years (range: 47-78years). For each SSLN, type (pure ground-glass or part-solid) was assessed by consensus and CTTA was conducted independently by each observer using a filtration-histogram technique. Different filters were used before histogram quantification: no filtration, fine, medium and coarse, followed by histogram quantification using mean intensity, standard deviation (SD), entropy, mean positive pixels (MPP), skewness and kurtosis. RESULTS We analyzed 13 pure ground-glass and 36 part-solid nodules corresponding to 16 adenocarcinomas in-situ (AIS), 5 minimally invasive adenocarcinomas (MIA) and 28 invasive adenocarcinomas (IVA). At uni- and multivariate analysis CTTA allowed discriminating between IVAs and AIS/MIA (P<0.05 and P=0.025, respectively) with the following histogram parameters: skewness using fine textures and kurtosis using coarse filtration for pure ground-glass nodules, and SD without filtration for part-solid nodules. CONCLUSION CTTA has the potential to differentiate AIS and MIA from IVA among SSLNs. However, our results require further validation on a larger cohort.
Collapse
Affiliation(s)
- J G Cohen
- Radiology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France.
| | - E Reymond
- Radiology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| | - M Medici
- Clinical Investigation Center for Innovative Technology (CICIT), Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| | - M Lederlin
- Department of Medical Imaging, Haut-Lévêque Teaching Hospital, 33000 Bordeaux, France
| | - S Lantuejoul
- Pathology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France; INSERM research unit 823, Albert Bonniot Institute, 38700 La Tronche, France
| | - F Laurent
- Department of Medical Imaging, Haut-Lévêque Teaching Hospital, 33000 Bordeaux, France
| | - A C Toffart
- INSERM research unit 823, Albert Bonniot Institute, 38700 La Tronche, France; Pneumology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| | - A Moreau-Gaudry
- Clinical Investigation Center for Innovative Technology (CICIT), Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| | - A Jankowski
- Radiology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| | - G R Ferretti
- Radiology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France; Pneumology department, Grenoble Alpes University Teaching Hospital, CS 10217, 38043 Grenoble cedex 9, France
| |
Collapse
|
30
|
Passalacqua A, Laurent F, Madadi-Kandjani E, Heylmun J, Fox R. An open-source quadrature-based population balance solver for OpenFOAM. Chem Eng Sci 2018. [DOI: 10.1016/j.ces.2017.10.043] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Rossi C, Vanhomwegen C, Laurent F. [HPV vaccination in boys and men : update and recommendations]. Rev Med Brux 2018; 39:352-358. [PMID: 30321000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
High-risk oncogenic HPVs (HR-HPV) are associated in men with pre-cancerous anal dysplasia, oropharyngeal, anal and penile cancer. Anogenital warts are induced by low-risk HPVs. These manifestations are increasing among men, and especially in some high-risk groups as men who have sex with men (MSM). This review targets HPV-associated disease epidemiology as well as safety, immunogenicity, and efficacy level of HPV vaccine in men. Obstacle and cost-effectiveness analysis of HPV vaccination are discussed. Three HPV vaccines are currently available in Belgium with the 9-valent (" 9HPV " - 6/11/16/18/31/33/45/52/58) offering protection against most of HPVassociated diseases. The safe 9-valent vaccine is efficient to prevent genital warts, anal dysplasia and it decreases the recurrence of genital warts and high grade anal neoplasia in MSM with or without HIV infection. In Europe, the 9-valent vaccine could prevent in men more than 350,000 genital warts, 5,485 oropharyngeal cancers, 2,303 anal cancers et 852 grade 2/3 intraepithelial neoplasia as well as 1,113 penile cancers per year. In the Federation Wallonie-Bruxelles, the vaccine coverage reaches currently 30 % in girls and is very low in boys and men.The Superior Health Council of Belgium (CSS) recommends since 2017 the gender-neutral HPV vaccination for people up to 26 years old and to immunocompromised patients. The implementation of the CSS HPV vaccine program and its acceptability among boys and men are discussed on the basis of the most recent epidemiologic data and available costeffectiveness analysis. Ways to overcome barriers to gender-neutral HPV vaccination are suggested.
Collapse
Affiliation(s)
- C Rossi
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| | - C Vanhomwegen
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| | - F Laurent
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| |
Collapse
|
32
|
Laurent F, Pingitore J, Rossi C. [Meningococcal B (4CMenB) vaccine : uptodate and recommendations]. Rev Med Brux 2018; 39:345-351. [PMID: 30320999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Neisseria meningitidis is the cause of relatively rare invasive infections, but with very important morbi-mortality. Vaccines are already available for serogroups A, C, W, Y. A new vaccine against meningococcus B is on the Belgian market since March 2017. Serogroup B is the most prevalent in Western countries. The target populations are children and teenager, since it is at this age that peaks in the incidence of meningococcal disease are observed. The development of this vaccine has been made possible by a new process named " reverse vaccinology ", which uses the complete genome sequencing of the bacterium. Current studies focus on the immunogenicity of the vaccine, which is good for both children and teenager. However, there are still many unknowns with this vaccine such as the duration of protection and its impact on the pharyngeal carriage. Another difficulty lies in the extrapolation of the immunogenicity data among a population because this vaccine consists of protein antigens and we know that the expression and prevalence of these antigens may vary between different strains of meningococci. In England, where the vaccine has been included in the vaccination calendar, beneficial effects are demonstrated on the incidence of invasive meningococcal infections. The toxicity profile is also reassuring, only classic side effects have been observed, such as fever and local reactions. In 2017, the High Health Council issued a favorable opinion for individual protection, without recommending at this stage a collective vaccination in Belgium. After a review of the most recent data on this new vaccine, we will try to draw conclusions.
Collapse
Affiliation(s)
- F Laurent
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| | - J Pingitore
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| | - C Rossi
- Service de Maladies infectieuses et tropicales, CHU Ambroise Paré, Mons
| |
Collapse
|
33
|
Wach J, Dinh A, Dutronc H, Sipahi OR, Candevir A, Valour F, Zeller V, Lustig S, Laurent F, Chidiac C, Ferry T. Tigecycline-based prolonged salvage therapy in patients presenting with complex bone and joint infection. Med Mal Infect 2017; 48:53-57. [PMID: 29031650 DOI: 10.1016/j.medmal.2017.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 11/09/2016] [Accepted: 09/01/2017] [Indexed: 11/19/2022]
Abstract
OBJECTIVES To assess the clinical experience of tigecycline-based salvage therapy in patients presenting with Bone and Joint Infections (BJI). PATIENTS AND METHODS Multicenter retrospective cohort study in France and Turkey (2007-2014). RESULTS Thirty-six patients (age 58.2±17.8 years; 21 men) were included. The most frequently isolated bacteria were Enterobacteriaceae and staphylococci. Tigecycline (50mg BID, mainly in combination (69.4%), mean duration of 58 days) was indicated for multidrug resistance (90.6%) and/or previous antibiotic intolerance (36.1%), and/or as second- or third-line therapy (69.4%). Six patients (16.7%) experienced early treatment discontinuation for adverse event (4 severe vomiting, 1 pancreatitis, 1 asymptomatic lipase increase). Clinical success was observed in 23 of 30 assessable patients who completed the tigecycline therapy (mean follow-up: 54.1±57.7 weeks). CONCLUSION Prolonged tigecycline-based therapy could be an alternative in patients presenting with BJI requiring salvage therapy, especially if multidrug-resistant Enterobacteriaceae and/or staphylococci are involved.
Collapse
Affiliation(s)
- J Wach
- Service de rhumatologie, centre hospitalier Lyon-Sud, hospices civils de Lyon, 69310 Pierre-Bénite, France
| | - A Dinh
- Service des maladies infectieuses, hôpital Raymond-Poincaré, Assistance publique-hôpitaux de Paris, 92380 Garches, France
| | - H Dutronc
- Service des maladies infectieuses, CHU de Bordeaux, 33000 Bordeaux, France
| | | | | | - F Valour
- Service des maladies infectieuses, hospices civils de Lyon, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69100 Lyon, France; Centre de référence des IOA complexes de Lyon, Lyon, France; Inserm U1111, centre international de recherche en infectiologie, CIRI, CNRS UMR5308, ENS de Lyon, UCBL1, 21, avenue Tony-Garnier, 69007 Lyon, France
| | - V Zeller
- Centre de référence des IOA complexes, hôpital Diaconesses-Croix-Saint-Simon, groupe hospitalier, 75012 Paris, France
| | - S Lustig
- Université Claude-Bernard Lyon 1, 69100 Lyon, France; Centre de référence des IOA complexes de Lyon, Lyon, France; Service de chirurgie orthopédique, centre Albert-Trillat, hôpital de la Croix-Rousse, hospices civils de Lyon, 69004 Lyon, France
| | - F Laurent
- Université Claude-Bernard Lyon 1, 69100 Lyon, France; Centre de référence des IOA complexes de Lyon, Lyon, France; Laboratoire de bactériologie, hôpital de la Croix-Rousse, hospices civils de Lyon, 69004 Lyon, France
| | - C Chidiac
- Service des maladies infectieuses, hospices civils de Lyon, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69100 Lyon, France; Centre de référence des IOA complexes de Lyon, Lyon, France; Inserm U1111, centre international de recherche en infectiologie, CIRI, CNRS UMR5308, ENS de Lyon, UCBL1, 21, avenue Tony-Garnier, 69007 Lyon, France
| | - T Ferry
- Service des maladies infectieuses, hospices civils de Lyon, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69100 Lyon, France; Centre de référence des IOA complexes de Lyon, Lyon, France; Inserm U1111, centre international de recherche en infectiologie, CIRI, CNRS UMR5308, ENS de Lyon, UCBL1, 21, avenue Tony-Garnier, 69007 Lyon, France.
| |
Collapse
|
34
|
Butin M, Martins-Simões P, Pichon B, Leyssene D, Bordes-Couecou S, Meugnier H, Rouard C, Lemaitre N, Schramm F, Kearns A, Spiliopoulou I, Hyyryläinen HL, Dumitrescu O, Vandenesch F, Dupieux C, Laurent F. Emergence and dissemination of a linezolid-resistant Staphylococcus capitis clone in Europe. J Antimicrob Chemother 2017; 72:1014-1020. [PMID: 27999045 DOI: 10.1093/jac/dkw516] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Accepted: 11/03/2016] [Indexed: 11/13/2022] Open
Abstract
Objectives We investigated the epidemiological, clinical, microbiological and genetic characteristics of linezolid-resistant (LZR) Staphylococcus capitis isolates from French ICUs, and compared them with LZR S. capitis isolates from other European countries. Methods All LZR isolates were subjected to antimicrobial susceptibility testing (AST) and the presence of cfr and optrA genes as well as mutations in the 23S rRNA and ribosomal proteins were investigated using specific PCR with sequencing. The genetic relationship between isolates was investigated using PFGE and WGS. Epidemiological data concerning LZR S. capitis were collected retrospectively in French microbiology laboratories. Results Twenty-one LZR isolates were studied: 9 from France, 11 from Greece and 1 from Finland. All were resistant to methicillin and aminoglycosides. In addition, this unusual AST profile was identified in S. capitis isolates from seven French hospitals, and represented up to 12% of the S. capitis isolates in one centre. A G2576T mutation in 23S rRNA was identified in all isolates; cfr and optrA genes were absent. All isolates belonged to the same clone on the basis of their PFGE profiles, whatever their geographical origin. WGS found at most 212 SNPs between core genomes of the LZR isolates. Conclusions We identified and characterized an LZR S. capitis clone disseminated in three European countries, harbouring the same multiple resistance and a G2576T mutation in the 23S rRNA. The possible unrecognized wider distribution of this clone, belonging to a species classically regarded as a low-virulence skin colonizer, is of major concern not least because of the increasing use of oxazolidinones.
Collapse
Affiliation(s)
- M Butin
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France
| | - P Martins-Simões
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - B Pichon
- National Infection Service, Public Health England, Colindale, London, UK
| | - D Leyssene
- Department of Bacteriology, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - S Bordes-Couecou
- Department of Bacteriology, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - H Meugnier
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - C Rouard
- Department of Bacteriology, Hôpital Antoine-Béclère, University Paris Sud, Clamart, France
| | - N Lemaitre
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, Lille, F-59000, France
| | - F Schramm
- Department of Bacteriology, CHRU de Strasbourg, EA7290 Early Bacterial Virulence, FMTS, Université de Strasbourg, Strasbourg, France
| | - A Kearns
- National Infection Service, Public Health England, Colindale, London, UK
| | - I Spiliopoulou
- National Staphylococcal Reference Laboratory, Department of Microbiology, School of Medicine, University of Patras, Patras, Greece
| | | | - O Dumitrescu
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - F Vandenesch
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - C Dupieux
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - F Laurent
- International Center for Infectiology Research (CIRI), INSERM U1111-CNRS UMR5308-ENS Lyon-University Claude Bernard Lyon 1, France.,Department of Bacteriology, Hospices Civils de Lyon, Lyon, France.,National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
35
|
Langlois M, Conrad A, Ducastelle-Lepretre S, Barraco F, Salles G, Roure-Sobas C, Laurent F, Chidiac C, Valour F, Ader F. Importance des caractéristiques hématologiques sur l’immunogénicité vaccinale après allogreffe de cellules souches hématopoïétiques. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Andrianosolo J, Ferry T, Boucher F, Shipkov H, Chateau J, Daoud F, Laurent F, Mojallal A, Chidiac C, Valour F. Ostéite chronique sur escarres pelviens : étude d’une stratégie de débridement, thérapie à pression négative (TPN), antibiothérapie (1 er temps) et lambeau de couverture (2 e temps). Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Chauvelot P, Ferry T, Triffault-Fillit C, Braun E, Lustig S, Fessy M, Laurent F, Chidiac C, Valour F. Infection ostéo-articulaire (IOA) à corynébactéries : étude de cohorte rétrospective dans un CRIOAc. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Triffault-Fillit C, Valour F, Tod M, Goutelle S, Lustig S, Fessy M, Laurent F, Chidiac C, Ferry T. Evènements indésirables (EI) de l’antibiothérapie probabiliste au cours des infections sur prothèse articulaire (IPA) : étude prospective en CRIOAc sur 5 ans. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Godet C, Couturaud F, Ragot S, Laurent F, Brun AL, Bergeron A, Cadranel J. [Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome ®]. Rev Mal Respir 2017; 34:581-587. [PMID: 28552257 DOI: 10.1016/j.rmr.2017.04.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 01/25/2017] [Indexed: 11/26/2022]
Abstract
BACKGROUND Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of patients with asthma. Its natural history includes possibly life-threatening exacerbations and evolution towards fixed obstructive ventilatory disorders or even irreversible lung fibrosis lesions. ABPA prognosis is directly associated with exacerbation control and the main objective of the treatment is to decrease their frequency and duration. Recommendations regarding dosage and duration of treatment are not very precise. The currently used combination of itraconazole and corticosteroid therapy has many limitations. The interests of a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) are to heighten antifungal lung tissue concentration, to circumvent drug interactions and decrease the potential toxicity of systemic antifungal treatments. Finally, this association leads to improved eradication of Aspergillus, thereby limiting the risk of side effects and the emergence of treatment-resistant Aspergillus strains. METHODS This is a phase II, multicentre, randomized, single blind, controlled therapeutic study, with the objective of comparing the potential benefit on exacerbation control of a maintenance therapy by LAmB nebulization. The main objective of the study is to compare the incidence of severe clinical exacerbations in ABPA treatment, between a maintenance treatment strategy with nebulized LAmB and a conventional strategy without antifungal maintenance therapy. EXPECTED RESULTS The results will guide practitioners in the management of ABPA treatments and help to define the place of aerosols of LAmB on "evidence base medicine" criteria.
Collapse
Affiliation(s)
- C Godet
- Service de maladies infectieuses et de médecine interne, CHU de Poitiers, 2, rue de la Miletrie, 86021 Poitiers cedex, France.
| | - F Couturaud
- Département de médecine interne et pneumologie, EA3878, CIC1412, CHU de Brest, 29200Brest, France
| | - S Ragot
- Inserm CIC 1402, UFR médecine pharmacie, université de Poitiers, centre d'investigation clinique, CHU de Poitiers, 86021Poitiers, France
| | - F Laurent
- Université de Bordeaux, centre de recherche cardio-thoracique de Bordeaux, Inserm U1045, CHU de Bordeaux, service d'imagerie diagnostique et thérapeutique, groupe hospitalier Sud, 33000 Bordeaux, France
| | - A L Brun
- Imaging department, Whittington hospital, N19 5NFLondon, Royaume-Uni
| | - A Bergeron
- Service de pneumologie, hôpital Saint-Louis, AP-HP, 75010Paris, France
| | - J Cadranel
- Service de pneumologie, hôpital Tenon, AP-HP, 75970Paris, France
| | | |
Collapse
|
40
|
Cameron DR, Lin YH, Trouillet-Assant S, Tafani V, Kostoulias X, Mouhtouris E, Skinner N, Visvanathan K, Baines SL, Howden B, Monk IR, Laurent F, Stinear TP, Howden BP, Peleg AY. Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors. Clin Microbiol Infect 2017; 23:767-773. [PMID: 28396035 DOI: 10.1016/j.cmi.2017.03.027] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 03/29/2017] [Accepted: 03/30/2017] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Vancomycin-intermediate Staphylococcus aureus (VISA) is associated with genetic changes that may also impact upon pathogenicity. In the current study, we compared the virulence of clinical VISA strains with their isogenic vancomycin-susceptible progenitors (VSSA). METHODS Production of the critical virulence protein, α toxin, was assessed using Western blot analysis and was correlated to agr activity using a bioluminescent agr-reporter. Cytotoxicity and intracellular persistence were compared ex vivo for VSSA and VISA within non-professional phagocytes (NPP). Virulence and host immune responses were further explored in vivo using a murine model of bacteraemia. RESULTS VISA isolates produced up to 20-fold less α toxin compared with VSSA, and this was corroborated by either loss of agr activity due to agr mutation, or altered agr activity in the absence of mutation. VISA were less cytotoxic towards NPP and were associated with enhanced intracellular persistence, suggesting that NPP may act as a reservoir for VISA. Infection with VSSA strains produced higher mortality in a murine bacteraemia model (≥90% 7-day mortality) compared with infection with VISA isolates (20% to 50%, p <0.001). Mice infected with VISA produced a dampened immune response (4.6-fold reduction in interleukin-6, p <0.001) and persistent organ bacterial growth was observed for VISA strains out to 7 days. CONCLUSIONS These findings highlight the remarkable adaptability of S. aureus, whereby, in addition to having reduced antibiotic susceptibility, VISA alter the expression of pathogenic factors to circumvent the host immune response to favour persistent infection over acute virulence.
Collapse
Affiliation(s)
- D R Cameron
- Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Australia
| | - Y-H Lin
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia
| | - S Trouillet-Assant
- Department of Microbiology, French National Reference Centre for Staphylococci, Hospices Civils de Lyon, International Centre of Infectiology Research, France
| | - V Tafani
- Department of Microbiology, French National Reference Centre for Staphylococci, Hospices Civils de Lyon, International Centre of Infectiology Research, France
| | - X Kostoulias
- Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Australia
| | - E Mouhtouris
- Department of Surgery, The University of Melbourne, Australia
| | - N Skinner
- Department of Medicine, The University of Melbourne, Australia
| | - K Visvanathan
- Department of Medicine, The University of Melbourne, Australia
| | - S L Baines
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia
| | - B Howden
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia
| | - I R Monk
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia
| | - F Laurent
- Department of Microbiology, French National Reference Centre for Staphylococci, Hospices Civils de Lyon, International Centre of Infectiology Research, France
| | - T P Stinear
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia
| | - B P Howden
- Department of Microbiology and Immunology, The University of Melbourne at the Doherty Institute of Infection & Immunity, Australia; Infectious Diseases and Microbiology Departments, Austin Health, Australia.
| | - A Y Peleg
- Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Australia; Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Australia.
| |
Collapse
|
41
|
Butin M, Rasigade JP, Subtil F, Martins-Simões P, Pralong C, Freydière AM, Vandenesch F, Tigaud S, Picaud JC, Laurent F. Vancomycin treatment is a risk factor for vancomycin-nonsusceptible Staphylococcus capitis sepsis in preterm neonates. Clin Microbiol Infect 2017; 23:839-844. [PMID: 28373147 DOI: 10.1016/j.cmi.2017.03.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 03/20/2017] [Accepted: 03/27/2017] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Multidrug-resistant, vancomycin-nonsusceptible Staphylococcus capitis is an emerging cause worldwide of late-onset sepsis (LOS) in preterm neonates. The pathophysiology and risk factors for S. capitis-related LOS are poorly understood, but we hypothesized that S. capitis LOS follows translocation from the gut microbiota rather than catheter invasion. The objective of this study was to investigate the risk factors of S. capitis LOS and gut colonization. METHODS We conducted a prospective single-centre cohort study of patients hospitalized in a tertiary-care unit (Lyon, France) from June 2011 to January 2012. S. capitis gut colonization was determined weekly from stool cultures. The determinants of gut colonization and LOS were established by multivariate Cox proportional hazards models. RESULTS Eighty-three (36.2%) of 229 patients had S. capitis-positive stool culture, and 28 (12.2%) developed S. capitis LOS during hospitalization. Independent risk factors for S. capitis LOS included prior administration of vancomycin independent of a previous LOS episode (hazard ratio 6.44, 95% confidence interval 2.15-19.3, p 0.001) and low birth weight (hazard ratio 0.72 per 100 g increase, 95% confidence interval 0.55-0.95, p 0.02). The prior administration of vancomycin was also an independent risk factor for S. capitis colonization (hazard ratio 3.45, 95% confidence interval 2.07-5.76, p <0.001), particularly in the first week of life and in noncolonized neonates. CONCLUSIONS Neonates treated with vancomycin are at a higher risk of LOS caused by vancomycin-nonsusceptible S. capitis. The use of vancomycin in neonates must urgently be optimized to limit the selection of vancomycin-nonsusceptible strains, for which alternative antibiotics are lacking.
Collapse
Affiliation(s)
- M Butin
- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure, France.
| | - J-P Rasigade
- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure, France; Institute of Infectious Agents, France; National Reference Center for Staphylococci, France
| | - F Subtil
- Department of Biostatistics, CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, France
| | - P Martins-Simões
- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure, France; National Reference Center for Staphylococci, France
| | - C Pralong
- Institute of Infectious Agents, France
| | | | - F Vandenesch
- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure, France; Institute of Infectious Agents, France; National Reference Center for Staphylococci, France
| | - S Tigaud
- Institute of Infectious Agents, France
| | - J-C Picaud
- Neonatal Intensive Care Unit, Northern Hospital Group, Hospices Civils de Lyon, Lyon, France
| | - F Laurent
- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure, France; Institute of Infectious Agents, France; National Reference Center for Staphylococci, France; Department of Microbiology-Mycology, Institut des Sciences Pharmaceutiques et Biologiques de Lyon, University of Lyon, France
| |
Collapse
|
42
|
Dournes G, Macey J, Blanchard E, Berger P, Laurent F. [MRI of the pulmonary parenchyma: Towards clinical applicability?]. Rev Pneumol Clin 2017; 73:40-49. [PMID: 28159433 DOI: 10.1016/j.pneumo.2016.12.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Accepted: 12/27/2016] [Indexed: 06/06/2023]
Abstract
Lung parenchyma has long been considered out of the scope of magnetic resonance imaging (MRI) clinical applicability. However, technological advances have emerged to soluce the technical difficulties and thus, applications in clinical practice have become realistic. Nevertheless, various approaches have been proposed and there is a need to synthetize the most recent literature data in order to envision a rationale to build lung MR protocols for clinical use. In addition, these technological innovations may modify the usual paradigms of lung MRI, which are still not consensual. Thus, lung MR protocols appear to be heterogeneous across expert centers in the current context. In this literature review, we ought to describe a rationale on the need to get an alternative to ionizing imaging modalities, in particular in the follow-up of patients with chronic lung diseases. We will describe the most recent technical advances regarding both morphological and functional MRI. Finally, we will conclude on the clinical applicability of MRI of the pulmonary parenchyma, as a routine or research tool.
Collapse
Affiliation(s)
- G Dournes
- Centre de recherche cardio-thoracique de Bordeaux, Inserm U1045, université Bordeaux-Segalen, CIC1401, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France; Service de radiologie, service de pneumologie, service d'exploration fonctionnelle respiratoire, CHU de Bordeaux, CIC1401, 33064 Pessac, France.
| | - J Macey
- Centre de recherche cardio-thoracique de Bordeaux, Inserm U1045, université Bordeaux-Segalen, CIC1401, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France; Service de radiologie, service de pneumologie, service d'exploration fonctionnelle respiratoire, CHU de Bordeaux, CIC1401, 33064 Pessac, France
| | - E Blanchard
- Service de radiologie, service de pneumologie, service d'exploration fonctionnelle respiratoire, CHU de Bordeaux, CIC1401, 33064 Pessac, France
| | - P Berger
- Centre de recherche cardio-thoracique de Bordeaux, Inserm U1045, université Bordeaux-Segalen, CIC1401, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France; Service de radiologie, service de pneumologie, service d'exploration fonctionnelle respiratoire, CHU de Bordeaux, CIC1401, 33064 Pessac, France
| | - F Laurent
- Centre de recherche cardio-thoracique de Bordeaux, Inserm U1045, université Bordeaux-Segalen, CIC1401, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France; Service de radiologie, service de pneumologie, service d'exploration fonctionnelle respiratoire, CHU de Bordeaux, CIC1401, 33064 Pessac, France
| |
Collapse
|
43
|
Soumagne T, Chardon M, Dournes G, Laurent L, Degano B, Laurent F, Dalphin J. Prévalence et caractéristique de l’emphysème dans la maladie de poumon de fermier : une étude prospective. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Hodille E, Delouere L, Bouveyron C, Meugnier H, Bes M, Tristan A, Laurent F, Vandenesch F, Lina G, Dumitrescu O. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect 2016; 47:152-157. [PMID: 27856079 DOI: 10.1016/j.medmal.2016.10.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 10/11/2016] [Indexed: 11/28/2022]
Abstract
OBJECTIVE We assessed the in vitro activity of ceftobiprole on 440 Staphylococcus aureus clinical strains isolated from bronchopulmonary infections (2010-2014). METHODS S. aureus isolates were characterized for methicillin resistance, PVL status, and clonal complex. All isolates were tested for minimal inhibitory concentrations (MIC) determination by broth microdilution method for ceftobiprole, ceftaroline fosamil, and comparator antibiotics (linezolid, tigecycline, vancomycin, and daptomycin). RESULTS A total of 325 (74%) strains were methicillin-susceptible S. aureus (MSSA) and 115 (26%) were methicillin-resistant S. aureus (MRSA); 105 (24%) S. aureus strains were PVL-positive, including 35.2% (37/105) MRSA and 64.8% (68/105) MSSA. Ceftobiprole was highly active against S. aureus with MIC90 of 1 mg/L, MICs ranging between 0.12 and 4mg/L (only one resistant strain, MIC of 4 mg/L). MIC50 and MIC90 were twice lower in MSSA than MRSA. Moreover, PVL+ MRSA were slightly more susceptible to ceftobiprole (MIC50 of 0.5 mg/L and MIC90 of 1 mg/L) than PVL- MRSA (MIC50 and MIC90 of 1 mg/L). The ceftobiprole-resistant strain was also resistant to ceftaroline fosamil and presented the D239L mutation in PBP2A. The comparator antibiotics were equally active on the strains tested, with MIC90 of 0.5 mg/L for ceftaroline fosamil, tigecycline, and daptomycin; 1 mg/L for vancomycin; and 2 mg/L for linezolid. CONCLUSIONS Our results suggest that ceftobiprole is highly active against S. aureus and is an effective alternative to vancomycin or linezolid in the management of staphylococcal pneumonia. However, close monitoring of isolates should be maintained to prevent resistant strain diffusion.
Collapse
Affiliation(s)
- E Hodille
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France.
| | - L Delouere
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - C Bouveyron
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - H Meugnier
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - M Bes
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - A Tristan
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - F Laurent
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - F Vandenesch
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - G Lina
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - O Dumitrescu
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| |
Collapse
|
45
|
Sokolowsky N, Rolland L, Vandenhende MA, Colin JY, Laurent F, Morlat P, Bonnet F, Beylot-Barry M. [Cutaneous lesions during hot-tub hypersensitivity pneumonitis: Pseudomonas folliculitis ?]. Ann Dermatol Venereol 2016; 144:290-294. [PMID: 27823913 DOI: 10.1016/j.annder.2016.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 07/01/2016] [Accepted: 10/05/2016] [Indexed: 11/26/2022]
Abstract
BACKGROUND Interstitial lung disease, cutaneous rash and elevated serum angiotensin converting enzyme (ACE) may suggest diagnoses other than sarcoidosis. PATIENTS AND METHODS A 58-year-old man had presented dyspnoea for 2 years with increased angiotensin-converting enzyme, as well as an interstitial syndrome and micronodules. The possibility of sarcoidosis was raised. Systemic corticosteroids resulted in improvement of the dyspnoea although it recurred on dose reduction. We noted fluctuating eczematous macules of the limbs with a histology of aspecific folliculitis. The identification of Mycobacterium avium complex (MAC) in the bronchoalveolar wash prompted us to initiate antimycobacterial therapy, but this was to no avail. Review of the CT-scan and questioning of the patient (daily use of a Jacuzzi for 7 years) resulted in diagnosis of hypersensitivity pneumonitis due to MAC. The cutaneous lesions were taken to indicate "hot tub folliculitis". Discontinuation of hot-tub use and a short course of oral corticosteroids resulted in healing within 4 months, with no recurrence at 2 years. DISCUSSION HTL is a form of hypersensitivity pneumonitis due to the presence of MAC in the water of Jacuzzis. This condition regresses spontaneously without treatment on discontinuation of Jacuzzi use. Hot-tub folliculitis due to Pseudomonas aeruginosa (PA) presents as macules and papules on covered skin areas (swimsuit) within 48hours of bathing and often declines within 2 weeks. CONCLUSION Our case is original as regards the concomitant lung and cutaneous involvement associated with Jacuzzi use, with an immunoallergic mechanism for the MAC and probably an infectious mechanism for the PA.
Collapse
Affiliation(s)
- N Sokolowsky
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France
| | - L Rolland
- Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France
| | - M-A Vandenhende
- Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France
| | - J-Y Colin
- Service de médecine interne, centre hospitalier, 20, avenue de Saint-Sordelin Plage, 17640 Vaux-sur-Mer, France
| | - F Laurent
- Service d'imagerie médicale - radiologie diagnostique et thérapeutique, hôpital Haut-Lévêque, CHU de Bordeaux, avenue de Magellan, 33600 Pessac, France
| | - P Morlat
- Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France
| | - F Bonnet
- Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France
| | - M Beylot-Barry
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, rue Jean-Burguet, 33076 Bordeaux, France.
| |
Collapse
|
46
|
Bouchiat C, Curtis S, Spiliopoulou I, Bes M, Cocuzza C, Codita I, Dupieux C, Giormezis N, Kearns A, Laurent F, Molinos S, Musumeci R, Prat C, Saadatian-Elahi M, Tacconelli E, Tristan A, Schulte B, Vandenesch F. MRSA infections among patients in the emergency department: a European multicentre study. J Antimicrob Chemother 2016; 72:372-375. [PMID: 27798212 DOI: 10.1093/jac/dkw431] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/09/2016] [Accepted: 09/13/2016] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND MRSA is a therapeutic concern worldwide, and a major agent of community-acquired skin and soft tissue infections (CA-SSTIs). While the US epidemiology of MRSA in CA-SSTIs is well described and reports the high prevalence of the USA300 clone, data on the European situation are lacking. OBJECTIVES To determine the prevalence and clonal characteristics of MRSA in CA-SSTIs in seven European emergency departments. PATIENTS AND METHODS From April to June 2015, patients presenting to the tertiary hospital emergency department with a Staphylococcus aureus CA-SSTI were prospectively enrolled. S. aureus isolates were characterized by antimicrobial susceptibility testing, detection of Panton-Valentine leucocidin encoding genes and spa-typing, MLST and/or DNA microarray. RESULTS Two-hundred and five cases of S. aureus-associated CA-SSTIs were included, comprising folliculitis, furuncles, abscesses, paronychia, impetigo, carbuncles and cellulitis. Of the 205 cases, we report an MRSA prevalence rate of 15.1%, with a north (0%) to south (29%) increasing gradient. Fifty-one isolates were Panton-Valentine leucocidin-positive (24.9%), whether MSSA or MRSA, with a heterogeneous distribution between countries. Clonal distribution of MSSA and MRSA showed high diversity, with no predominant circulating clone and no archetypical USA300 CA-MRSA clone. CONCLUSIONS This original prospective multicentre study highlights stark differences in European MRSA epidemiology compared with the USA, and that the USA300 CA-MRSA clone is not predominant among community-infected patients in Europe.
Collapse
Affiliation(s)
- C Bouchiat
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | - S Curtis
- Staphylococcus Reference Service, Public Health England, 61 Colindale Avenue London NW9 5EQ, UK
| | - I Spiliopoulou
- National Reference Laboratory for Staphylococci, University of Patras, University Campus, Rion 26504, Patras, Greece
| | - M Bes
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | - C Cocuzza
- Laboratory of Clinical Microbiology and Virology, University of Milano-Bicocca, Via Cadore 48, Monza, Italy
| | - I Codita
- Cantacuzino National Institute of Research, Splaiul Independentei 103, RO-050096 Bucharest, Romania
| | - C Dupieux
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | - N Giormezis
- National Reference Laboratory for Staphylococci, University of Patras, University Campus, Rion 26504, Patras, Greece
| | - A Kearns
- Staphylococcus Reference Service, Public Health England, 61 Colindale Avenue London NW9 5EQ, UK
| | - F Laurent
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | - S Molinos
- Servei de Microbiologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,CIBER Enfermedades Respiratorias. Carretera del Canyet s/n. 08916 Badalona, Spain
| | - R Musumeci
- Laboratory of Clinical Microbiology and Virology, University of Milano-Bicocca, Via Cadore 48, Monza, Italy
| | - C Prat
- Servei de Microbiologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,CIBER Enfermedades Respiratorias. Carretera del Canyet s/n. 08916 Badalona, Spain
| | - M Saadatian-Elahi
- Epidemiology unit, Hospices Civils de Lyon, Place d'Arsonval, 69008 Lyon, France
| | - E Tacconelli
- Division of Infectious Diseases, Department of Internal Medicine 1, University Hospital Tuebingen, Geissweg 3, 72076 Tuebingen, Germany
| | - A Tristan
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | - B Schulte
- Institut für Mikrobiologie und Infektionsmedizin, University Hospital Tuebingen, Auf der Morgenstelle 28, 72076 Tuebingen, Germany
| | - F Vandenesch
- National Reference Center for Staphylococci, 59 Bd Louis Pinel, 69677 Bron cedex, Lyon, France
| | | |
Collapse
|
47
|
Valour F, Laurent F, Ferry T. Pristinamycin in the treatment of MSSA bone and joint infection-authors' response. J Antimicrob Chemother 2016; 71:3318. [PMID: 27585967 DOI: 10.1093/jac/dkw341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- F Valour
- Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la Croix-Rousse, 69004 Lyon, France .,French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de Lyon, Lyon, France.,International Centre for Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, France
| | - F Laurent
- French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de Lyon, Lyon, France.,International Centre for Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, France.,Laboratory of Bacteriology, French National Reference Centre for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - T Ferry
- Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la Croix-Rousse, 69004 Lyon, France.,French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de Lyon, Lyon, France.,International Centre for Research in Infectiology, INSERM U1111, Claude Bernard Lyon 1 University, Lyon, France
| | | |
Collapse
|
48
|
Ben Said M, Hays S, Bonfils M, Jourdes E, Rasigade JP, Laurent F, Picaud JC. Late-onset sepsis due to Staphylococcus capitis 'neonatalis' in low-birthweight infants: a new entity? J Hosp Infect 2016; 94:95-8. [PMID: 27424947 DOI: 10.1016/j.jhin.2016.06.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Accepted: 06/10/2016] [Indexed: 10/21/2022]
Abstract
During hospitalization, sepsis occurs in one of every five very-low-birthweight infants. The emergence of Staphylococcus capitis (SC)-related sepsis in preterm infants was observed recently. This study aimed to evaluate the clinical severity of SC-related sepsis in preterm infants. Of the 105 infants who presented with sepsis related to coagulase-negative staphylococci, 74 were SC. Severe morbidity was more common in the SC group (55.4%) than in the non-SC coagulase-negative staphylococci group (32.0%) (P=0.03). Multi-variate analysis identified SC-related sepsis as an independent risk factor for severe morbidity.
Collapse
Affiliation(s)
- M Ben Said
- Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, Lyon, France; Faculty of Medicine of Tunis, University of Tunis El-Manar, Tunis, Tunisia
| | - S Hays
- Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, Lyon, France; Rhone-Alpes Human Nutrition Research Centre, Pierre Bénite, France
| | - M Bonfils
- Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - E Jourdes
- Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - J-P Rasigade
- Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France; Department of Bacteriology - National Reference Centre for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - F Laurent
- Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France; Department of Bacteriology - National Reference Centre for Staphylococci, Hospices Civils de Lyon, Lyon, France
| | - J-C Picaud
- Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, Lyon, France; Rhone-Alpes Human Nutrition Research Centre, Pierre Bénite, France; Lyon-Sud Charles Merieux Medical School, Claude Bernard University Lyon 1, Pierre Bénite, France.
| |
Collapse
|
49
|
Trouillet-Assant S, Tafani V, Cameron D, Valour F, Peleg A, Laurent F. COL 6-01 - Le compartiment intracellulaire : un réservoir bactérien pour les souches VISA. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30281-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
Trouillet-Assant S, Dupieux C, Camus C, Chidiac C, Lustig S, Ferry T, Laurent F, Valour F. IOA-06 - Traitement des infections ostéo-articulaires à Staphylococcus aureus : synergie intra-ostéoblastique de la daptomycine avec l’oxacilline et la ceftaroline. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30415-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|